Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Farmers Insurance
US Department of Justice

Generated: March 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019441

« Back to Dashboard

NDA 019441 describes NOVOLIN 70/30, which is a drug marketed by Novo Nordisk Inc and is included in two NDAs. It is available from three suppliers. Additional details are available on the NOVOLIN 70/30 profile page.

The generic ingredient in NOVOLIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are thirty-nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.
Summary for 019441

Profile for product number 001

Approval Date:Jul 11, 1986TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Federal Trade Commission
Boehringer Ingelheim
US Department of Justice
Daiichi Sankyo
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.